Matrix and Clinton Foundation for AIDS therapy
Hyderabad-based Matrix Labs and Clinton HIV/AIDS Initiative (CHAI), Mylan Inc., have signed an agreement to offer once-daily dose of second-line regimen of four anti-retroviral (ARV) therapies offering affordable treatment for HIV/AIDS patients in the developing countries for under $500 per patient a year.
Former US President Bill Clinton, Mylan Chairman and CEO Robert J. Coury, and Matrix Laboratories founder and vice-chairman N. Prasad announced the agreement at New York.
This agreement provides Atazanavir (ATV), Ritonavir (RTV), Tenofovir (TDF), and Lamivudine (3TC) would be available in three pills, with Tenofovir and Lamivudine combined into a single pill. All the four drugs were needed to enable once-daily treatment of patients who have developed resistance to standard first-line ARVs.